Exelixis Inc.
Rating
Updated: Sep 2, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United St...
Latest News
4 days ago · marketbeat.com
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3BExelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer.
5 days ago · seekingalpha.com
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptExelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
6 days ago · marketbeat.com
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp HurdleExelixis NASDAQ: EXEL executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.
7 days ago · zacks.com
Here's Why Exelixis (EXEL) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
7 days ago · marketbeat.com
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer FranchisesExelixis NASDAQ: EXEL executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.
8 days ago · seekingalpha.com
Exelixis: The FDA Delay Costs Less Than The Market ThinksThe FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. At a 10% discount rate, three months reduces an asset's present value by only 2.35%, far less than Exelixis initially lost. CABOMETYX continues growing, and 2026 guidance includes no zanzalintinib launch revenue.
10 days ago · benzinga.com
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs InOn Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for metastatic colorectal cancer by three months.
10 days ago · reuters.com
U.S. FDA extends review of Exelixis' cancer drugThe U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
10 days ago · defenseworld.net
Baird Financial Group Inc. Raises Holdings in Exelixis, Inc. $EXELBaird Financial Group Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 7,459.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 437,138 shares of the biotechnology company's stock after acquiring an additional 431,355 shares during the period. Baird
12 days ago · seekingalpha.com
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptExelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove EXEL